PTC Therapeutics (PTCT) stock soared 5.28% in the pre-market trading session on Friday, following the release of the company's strong financial results for 2024 and encouraging updates on its promising drug pipeline.

The biopharmaceutical company reported impressive financial performance for the fourth quarter and full year 2024, exceeding expectations. Highlights included:

• Q4 revenue of $213 million and full year 2024 revenue of $807 million, surpassing guidance.
• Cash position of over $1.1 billion at the end of 2024, further bolstered by a $1 billion upfront payment from Novartis in January 2025.
• Strong performance from the company's DMD franchise, which generated $547 million in revenue for the full year 2024.

Additionally, PTC Therapeutics provided promising updates on its drug pipeline, including:

• Achieving all clinical and regulatory milestones on schedule in 2024, with four FDA approval applications, one already approved and others under review.
• Preparing for multiple potential product launches in 2025, including sepiapterin for PKU and vatiquinone for Friedreich's ataxia, which could significantly enhance their commercial portfolio.
• Positive developments in the PTC518 Huntington's disease program, including a global development and commercialization collaboration with Novartis.

Analysts have also expressed optimism about PTC Therapeutics' prospects. William Blair's Sami Corwin and JP Morgan's Eric Joseph both reiterated their "Buy" ratings, citing the company's strong commercial foundation, strategic partnerships, and promising clinical catalysts.